PARIS & CAMBRIDGE, England--(BUSINESS WIRE)--Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics is pleased to announce the addition of new members to its Board as the Company prepares for the next stages of growth.
Following the Annual General Meeting of the 29th June, 2015 in Paris where all resolutions were approved by shareholders the Company announces the retirement of Fouad Tarabah, a non-executive director and the appointment of two new non-executive directors, Dr Andrew Heath and Alan Howard.
The new appointments bring a wealth of experience from the life sciences sector, covering both commercial and medical expertise, which will be crucial as Novacyt continues to expand globally.
The Board would like to thank Fouad for his support and commitment to Novacyt who has been a Board director since its floatation in 2012.
Dr Andrew Heath joins Novacyt with significant knowledge in capital markets and with international experience in marketing and sales, R & D and business development. Andrew currently serves as Deputy Chairman of Oxford Biomedica plc (since 2010) and as a non-executive director of XL TechGroup Inc., Anew Inc., and IHT Llc. He served as a director of the BioIndustry Association from 2005-2012, and from 1997 to 2008 as Chief Executive Officer of Protherics plc, taking the company from 30 to 350 staff and managing its eventual acquisition by BTG for £220 million. Prior to this, he held senior positions at Astra AB and Astra USA, including Vice President Marketing & Sales, and at Glaxo Sweden as Associate Medical Director.
Mr Alan Howard, a trained barrister, was most recently Chief Executive of the European Society of Medical Oncology (ESMO), joins the Board having worked extensively in healthcare markets enabling organisations to achieve best-in-class standards of governance, corporate compliance and regulatory market compliance. His experience includes Legal and Regulatory Affairs Director of Medtronic Europe based in Paris, CEO of the professional body European Society of Cardiology (ESC), and then more recently CEO of ESMO where he is credited for driving membership from 2500 to over 8000 and building ESMO to a highly respected global brand in cancer.
Graham Mullis, Group CEO Novacyt, commented “We are delighted to appoint Andrew and Alan to the Board. This is an exciting time at Novacyt and the Company welcomes the significant relevant experience that both executives bring to the Board as we develop our next phase of corporate growth strategy.”
- Ends –